Media Releases and Task Force Announcements

Media Releases and Task Force Announcements2021-02-26T17:28:04-05:00

New study will assess impact of COVID-19 vaccination on Canadians with immune-mediated inflammatory disease

More than 7 million Canadians suffer from immune-mediated inflammatory diseases (IMID) such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and related conditions. It is important that they too be protected from COVID-19, yet the effectiveness and safety of vaccines for Canadians with these health issues has not been thoroughly investigated. The COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG) are supporting a nationwide study that will assess COVID-19 vaccine effectiveness, safety and vaccine hesitancy in this potentially vulnerable group of people.

September 9, 2021|Media Releases|

Study results show subtle differences in antibody response between Pfizer and Moderna vaccines for residents of long-term care

This CITF-funded research, which is in pre-print, was led by Lunenfeld-Tanenbaum Research Institute (LTRI) senior scientists Dr. Anne-Claude Gingras and Dr. Allison McGeer and reveals that long-term care (LTC) residents in Ontario who received the Pfizer vaccine had lower antibody responses to Alpha, Beta and Gamma than those vaccinated with the Moderna vaccine. The Delta variant was not assessed.

August 17, 2021|Long-term care & seniors, Media Releases|

Researchers to study COVID-19 vaccine efficacy and safety in transplant patients

A national research study has just launched to investigate the effectiveness and safety of COVID-19 vaccines in transplant recipients. The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing over $2.84 million in this research study, based at University Health Network and called PREVenT COVID, short for Prospective Evaluation of COVID-19 Vaccine in Transplant Recipients: A National Strategy.

July 22, 2021|Media Releases|

How well do COVID-19 vaccines work in people with cancer, immune deficiencies and other populations with health vulnerabilities?

The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing more than $8 million on four studies led by researchers at The Ottawa Hospital and the University of Ottawa. The studies aim to answer important questions about COVID-19 vaccines, including how well they work in people with cancer and with inherited and medication-related immune deficiencies. One of the studies will also be looking at post-COVID-19 conditions.

July 15, 2021|Media Releases|

Researchers to investigate vaccine uptake, efficacy and side effects in vulnerable urban populations

Urban centres across Canada are home to many vulnerable populations who are more at risk of acquiring SARS-CoV-2 and developing serious complications from COVID-19. The Government of Canada, through the COVID-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG), is investing approximately $770,000 in a new study that will investigate the uptake, effectiveness, and side effects of COVID-19 vaccines among members of vulnerable urban populations in Canada.

July 14, 2021|Media Releases|

Canadian researchers to study best approaches to possible adverse events following COVID-19 vaccination

The Government of Canada, through its COVID-19 Immunity Task Force (CITF) and Vaccine Surveillance Reference Group (VSRG), is investing approximately $800,000 for a study that aims to further improve Canada’s identification and response to adverse events people may experience following COVID-19 vaccination across 10 provinces.

July 13, 2021|Media Releases|

Study reveals children and youth had highest rates of SARS-CoV-2 infection in Canada before third wave

Canada’s most representative study to date investigating how many Canadians have antibodies to SARS-CoV-2, the virus causing COVID-19, reveals a mere 2.6% of Canadians tested between November 2020 and April 2021 had developed antibodies resulting from a past infection. Another 1% of Canadians had antibodies due to vaccination, reflecting the fact that vaccination was not widely available during the survey period. This brings the total percentage of Canadians with some form of immunity before the third wave to 3.6%. These data come from Statistics Canada’s Canadian COVID-19 Antibody and Health Survey (CCAHS), done in partnership with Canada’s COVID-19 Immunity Task Force (CITF), the Public Health Agency of Canada, and Health Canada.

Largest international review of serosurveys, done by Canadians, suggests that the global population remains vulnerable to COVID-19

SeroTracker, a Canadian research group, has published the largest study to date on the global spread of SARS-CoV-2 in the journal PLOS One. The study examined antibody survey data, which were published from January to December 2020, from 9.3 million people in 74 countries and found that the number of people who had a SARS-COV-2 infection, although widely variable globally, remained fairly low in the general population.

Go to Top